Company profile: Arrowhead Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of RNAi therapeutics for genetically driven diseases with protein overproduction, leveraging the TRiM platform for ligand-mediated, tissue-specific delivery. Pipeline includes plozasiran (ARO-APOC3) for hypertriglyceridemia, zodasiran (ARO-ANG3) for mixed dyslipidemia, and ARO programs targeting RAGE, MUC5AC, and MMP7 for inflammatory and muco-obstructive lung diseases and idiopathic pulmonary fibrosis.
Products and services
- Plozasiran (ARO-APOC3): An RNAi-based investigational drug that treats hypertriglyceridemia by reducing APOC3 protein levels, focusing on APOC3 suppression
- TRiM Platform: A modular technology using ligand-mediated delivery to achieve tissue-specific targeting for RNAi therapeutics, streamlining manufacturing processes and reducing overall production costs
- Zodasiran (ARO-ANG3): A protein-targeting investigational RNAi drug engineered to treat mixed dyslipidemia by specifically targeting the ANGPTL3 protein
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Arrowhead Pharmaceuticals
Biosplice
HQ: United States
Website
- Description: Provider of therapeutic solutions and clinical trials for tissue-level regeneration, developing therapies that modulate alternative splicing via CLK/DYRK kinase inhibition to treat diseases like osteoarthritis and cancer. Offerings include Lorecivivint, an injectable small molecule for knee osteoarthritis to reduce pain, improve function, and protect cartilage, with trials evaluating safety, efficacy, and dosing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biosplice company profile →
New Haven Pharmaceuticals
HQ: United States
Website
- Description: Provider of prescription pharmaceuticals utilizing drugs or GRAS active pharmaceutical ingredients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full New Haven Pharmaceuticals company profile →
Schwarz Pharma
HQ: Germany
Website
- Description: Provider of pharmaceutical product development, bringing approved and late-stage new compounds with complementary therapeutic and geographic focus, supported by strong talent and cultural fit.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Schwarz Pharma company profile →
Vicore Pharma
HQ: Sweden
Website
- Description: Provider of pharmaceuticals for severe lung disorders, developing drugs acting through the angiotensin II type 2 (AT2) receptor, including buloxibutid (C21), an orally available ATRAG in phase 2a for idiopathic pulmonary fibrosis (IPF) with orphan drug designation in the EU, and Almee, a digital therapeutic based on cognitive behavioral therapy to address the psychological impact of pulmonary fibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vicore Pharma company profile →
KAI Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel therapeutics through drug discovery and development, with multiple clinical-stage programs in cardiovascular disease, kidney disease, and pain; lead candidate KAI-9803 is in Phase 2b (PROTECTION AMI) evaluating reduction of myocardial injury in heart attack.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full KAI Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Arrowhead Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Arrowhead Pharmaceuticals
2.2 - Growth funds investing in similar companies to Arrowhead Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Arrowhead Pharmaceuticals
4.2 - Public trading comparable groups for Arrowhead Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →